Aplastic anaemia as an autoimmune complication of thymomaARCASOY, Murat O; GOCKERMAN, Jon P.British journal of haematology. 2007, Vol 137, Num 4, pp 272-272, issn 0007-1048, 1 p.Article

Monoclonal antibody therapy in the treatment of non-Hodgkin lymphomaMCCUNE, Steven L; GOCKERMAN, Jon P; RIZZIERI, David A et al.JAMA, the journal of the American Medical Association. 2001, Vol 286, Num 10, pp 1149-1152, issn 0098-7484Article

Barriers to the participation of African-American patients with Cancer in clinical trials: A pilot studyADVANI, Anjali S; ATKESON, Benjamin; BROWN, Carrie L et al.Cancer. 2003, Vol 97, Num 6, pp 1499-1506, issn 0008-543X, 8 p.Article

Phase I evaluation of Prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemiaRIZZIERI, David A; IBOM, Valerie K; GASPARETTO, Christina et al.Clinical cancer research. 2003, Vol 9, Num 2, pp 663-668, issn 1078-0432, 6 p.Article

A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate CancerARMSTRONG, Andrew J; CREEL, Patricia; HURWITZ, Herbert et al.Clinical cancer research (Print). 2008, Vol 14, Num 19, pp 6270-6276, issn 1078-0432, 7 p.Article

Progressive immunoglobulin gene mutations in chronic lymphocytic leukemia : evidence for antigen-driven intraclonal diversificationVOLKHEIMER, Alicia D; WEINBERG, J. Brice; BEASLEY, Bethany E et al.Blood. 2007, Vol 109, Num 4, pp 1559-1567, issn 0006-4971, 9 p.Article

Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemiaWEINBERG, J. Brice; VOLKHEIMER, Alicia D; RIZZIERI, David A et al.American journal of hematology. 2007, Vol 82, Num 12, pp 1063-1070, issn 0361-8609, 8 p.Article

A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)BULLOCK, Karen E; PETROS, William P; MEADOWS, Kellen L et al.Cancer chemotherapy and pharmacology. 2011, Vol 67, Num 2, pp 465-474, issn 0344-5704, 10 p.Article

Outcomes of Patients Who Undergo Aggressive Induction Therapy for Secondary Acute Myeloid LeukemiaRIZZIERI, David A; O'BRIEN, Jenny A; MOORE, Joseph O et al.Cancer. 2009, Vol 115, Num 13, pp 2922-2929, issn 0008-543X, 8 p.Article

Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid: Results in 98 patientsSAFFORD, Shawn D; COLEMAN, R. Edward; GOCKERMAN, Jon P et al.Cancer. 2004, Vol 101, Num 9, pp 1987-1993, issn 0008-543X, 7 p.Article

Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular LymphomaSCHUSTER, Stephen J; NEELAPU, Sattva S; MCGAUGHEY, Dean S et al.Journal of clinical oncology. 2011, Vol 29, Num 20, pp 2787-2794, issn 0732-183X, 8 p.Article

Clinicopathologic Findings in High-Grade B-Cell Lymphomas With Typical Burkitt Morphologic Features but Lacking the MYC TranslocationSEVILLA, Deborah W; GONG, Jerald Z; GOODMAN, Barbara K et al.American journal of clinical pathology. 2007, Vol 128, Num 6, pp 981-991, issn 0002-9173, 11 p.Article

Phase 1 trial study of ¹³¹I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphomaRIZZIERI, David A; AKABANI, Gamal; PEGRAM, Charles N et al.Blood. 2004, Vol 104, Num 3, pp 642-648, issn 0006-4971, 7 p.Article

A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients With Relapsed/Refractory Multiple MyelomaHELD, Lauren A; RIZZIERI, David; LONG, Gwynn D et al.Cancer investigation. 2013, Vol 31, Num 1-10, pp 172-176, issn 0735-7907, 5 p.Article

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma : Cancer and Leukemia Group B study 19801DEANGELO, Daniel J; DAOHAI YU; JOHNSON, Jeffrey L et al.Blood. 2007, Vol 109, Num 12, pp 5136-5142, issn 0006-4971, 7 p.Article

Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell Expansion correlations with clinical responseGLUCK, William Larry; HURST, Deborah; DIFRANCESCO, Anita et al.Clinical cancer research. 2004, Vol 10, Num 7, pp 2253-2264, issn 1078-0432, 12 p.Article

Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphomaBASS, Adam J; GOCKERMAN, Jon P; RIZZIERI, David A et al.Journal of clinical oncology. 2002, Vol 20, Num 13, pp 2995-3000, issn 0732-183XArticle

Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemiaRIZZIERI, David A; BASS, Adam J; JACOBSON, Robert et al.Journal of clinical oncology. 2002, Vol 20, Num 3, pp 674-679, issn 0732-183XArticle

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment targetCHRISTENSEN, Dale J; CHEN, Youwei; GOCKERMAN, Jon P et al.Blood. 2011, Vol 118, Num 15, pp 4150-4158, issn 0006-4971, 9 p.Article

Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease : Cure balanced against complicationsKOONTZ, Bridget F; KIRKPATRICK, John P; CLOUGH, Robert W et al.Journal of clinical oncology. 2006, Vol 24, Num 4, pp 605-611, issn 0732-183X, 7 p.Article

Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphomaRIZZIERI, David A; SAND, Gregory J; FOSTER, Tracy et al.Cancer. 2004, Vol 100, Num 11, pp 2408-2414, issn 0008-543X, 7 p.Article

Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. DiscussionSAFFORD, Shawn D; COLEMAN, R. Edward; WEIGEL, Ronald J et al.Surgery. 2003, Vol 134, Num 6, pp 956-963, issn 0039-6060, 8 p.Conference Paper

Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma. Cancer and Leukemia Group B studies 8852 and 8854BARTLETT, Nancy L; PETRONI, Gina R; PARKER, Barbara A et al.Cancer. 2001, Vol 92, Num 2, pp 207-217, issn 0008-543XArticle